Suppr超能文献

静脉血栓栓塞的预防

Prophylaxis of venous thromboembolism.

作者信息

Kakkar V V, Stringer M D

机构信息

Thrombosis Research Institute, Chelsea, London, England, United Kingdom.

出版信息

World J Surg. 1990 Sep-Oct;14(5):670-8. doi: 10.1007/BF01658824.

Abstract

The objective of prophylaxis in venous thromboembolism is, first, to prevent fatal pulmonary embolism and, second, to reduce the morbidity associated with deep vein thrombosis (DVT) and the postphlebitic limb. This should now be standard practice for most patients over 40 years of age undergoing major surgery and for younger patients with a history of venous thromboembolism. Particularly high-risk groups include patients over 60 years of age undergoing major surgery, those with malignancy, and those requiring hip operations. Low-dose subcutaneous heparin 5,000 IU commencing 2 hours preoperatively and continuing 12 hourly until the patient is fully mobile is unequivocally effective in preventing DVT in medical and surgical patients and, most importantly, significantly reduces the incidence of fatal postoperative pulmonary embolism and total mortality. Such prophylaxis, in the presence of established DVT, also limits proximal clot propagation, which is the precursor of major pulmonary embolism. Low-dose heparin prophylaxis is associated with a small risk of bleeding complications, evidenced mostly by an increased frequency of wound hematoma rather than major clinical hemorrhage. Low molecular weight heparin fragments (e.g., Fragmin, Choay, Enoxaparine) are emerging as useful alternative agents, having the advantage of once daily administration and yet providing similar efficacy in the prevention of DVT. Mechanical methods of prevention which counteract venous stasis, such as graduated elastic compression stockings, are also useful in protecting against DVT but have not been shown to prevent fatal postoperative pulmonary embolism. They are recommended particularly for patients in whom heparin prophylaxis is best avoided (e.g., neurosurgery) and possibly in combination with heparin in very high-risk patients.

摘要

静脉血栓栓塞症预防的目标,首先是预防致命性肺栓塞,其次是降低与深静脉血栓形成(DVT)及血栓形成后肢体相关的发病率。对于大多数40岁以上接受大手术的患者以及有静脉血栓栓塞症病史的年轻患者而言,这现在应成为标准做法。特别高危的群体包括60岁以上接受大手术的患者、患有恶性肿瘤的患者以及需要进行髋关节手术的患者。术前2小时开始皮下注射低剂量肝素5000 IU,并每12小时持续注射一次,直至患者完全能够活动,这在预防内科和外科患者的DVT方面具有明确疗效,而且最重要的是,能显著降低术后致命性肺栓塞的发生率及总死亡率。在已确诊DVT的情况下,这种预防措施还能限制近端血栓扩展,而近端血栓扩展是严重肺栓塞的先兆。低剂量肝素预防措施会有少量出血并发症风险,主要表现为伤口血肿发生率增加,而非严重临床出血。低分子量肝素片段(如速碧林、克赛、依诺肝素)正成为有用的替代药物,具有每日给药一次的优势,且在预防DVT方面疗效相似。对抗静脉淤滞的机械预防方法,如分级弹力压缩袜,在预防DVT方面也有用,但尚未证明能预防术后致命性肺栓塞。特别推荐将其用于最好避免使用肝素预防的患者(如神经外科手术患者),对于极高危患者可能也可与肝素联合使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验